This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Cefodizime is a broad-spectrum, third-generation cephalosporin used to treat serious infections caused by susceptible bacteria.

Generic Name
Cefodizime
DrugBank Accession Number
DB13470
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 584.669
Monoisotopic: 584.027629784
Chemical Formula
C20H20N6O7S4
Synonyms
  • CDZM
  • Cefodizima
  • Cefodizime
  • Cefodizimum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCefodizime may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefodizime.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Cefodizime.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefodizime is combined with Acenocoumarol.
AcetaminophenCefodizime may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefodizime.
AclidiniumCefodizime may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineCefodizime may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirThe risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Cefodizime.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cefodizime sodiumHC1T51593A86329-79-5WBOBLQIRACJNPA-AEKYOGSZSA-L

Categories

ATC Codes
J01DD09 — Cefodizime
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporins
Alternative Parents
N-acyl-alpha amino acids and derivatives / 2,4,5-trisubstituted thiazoles / 2,4-disubstituted thiazoles / Alkylarylthioethers / 1,3-thiazines / 2-amino-1,3-thiazoles / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides
show 12 more
Substituents
1,3-thiazol-2-amine / 2,4,5-trisubstituted 1,3-thiazole / 2,4-disubstituted 1,3-thiazole / Alkylarylthioether / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl thioether
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, 1,3-thiazole, oxime O-ether (CHEBI:63214)
Affected organisms
Not Available

Chemical Identifiers

UNII
Z31298J4HQ
CAS number
69739-16-8
InChI Key
XDZKBRJLTGRPSS-BGZQYGJUSA-N
InChI
InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(CSC3=NC(C)=C(CC(O)=O)S3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

References

General References
  1. AIFA Product Information: Modivid (cefodizime) powder for solution for injection [Link]
Human Metabolome Database
HMDB0041850
KEGG Drug
D07643
ChemSpider
4514859
BindingDB
50422690
RxNav
20485
ChEBI
63214
ChEMBL
CHEMBL2303613
ZINC
ZINC000003830421
Wikipedia
Cefodizime

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Parenteral1 G/4ML
Injection, powder, for solutionIntravenous; Parenteral2 G/10ML
Injection, powder, for solutionParenteral1 G/4ML
Injection, powder, for solutionParenteral250 MG/2ML
Injection, powder, for solutionParenteral500 MG/2ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.068 mg/mLALOGPS
logP1.07ALOGPS
logP0.24ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)2.68ChemAxon
pKa (Strongest Basic)3.45ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area197.4 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity136.93 m3·mol-1ChemAxon
Polarizability56.47 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:42 / Updated at May 05, 2021 20:31